Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Other Non-Current Liabilities (2021 - 2026)

Indivior Pharmaceuticals has reported Other Non-Current Liabilities over the past 6 years, most recently at $21.0 million for Q1 2026.

  • For Q1 2026, Other Non-Current Liabilities rose 23.53% year-over-year to $21.0 million; the TTM value through Mar 2026 reached $21.0 million, up 23.53%, while the annual FY2025 figure was $21.0 million, 16.67% up from the prior year.
  • Other Non-Current Liabilities for Q1 2026 was $21.0 million at Indivior Pharmaceuticals, roughly flat from $21.0 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $428.0 million in Q4 2022 and troughed at -$369.0 million in Q3 2023.
  • A 5-year average of -$84.2 million and a median of $18.0 million in 2024 define the central range for Other Non-Current Liabilities.
  • Biggest five-year swings in Other Non-Current Liabilities: soared 463.16% in 2022 and later crashed 92.76% in 2023.
  • Year by year, Other Non-Current Liabilities stood at $428.0 million in 2022, then crashed by 92.76% to $31.0 million in 2023, then crashed by 41.94% to $18.0 million in 2024, then rose by 16.67% to $21.0 million in 2025, then changed by 0.0% to $21.0 million in 2026.
  • Business Quant data shows Other Non-Current Liabilities for INDV at $21.0 million in Q1 2026, $21.0 million in Q4 2025, and $30.0 million in Q3 2025.